Treprostinil for pulmonary hypertension: real-world outcomes
Treatments studied
Part of Lungs & breathing clinical trials.
This study looks at how well treprostinil, a medication given by injection, works for people with pulmonary hypertension. It aims to gather real-world data to understand treatment trends and outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of pulmonary arterial hypertension (PAH), a type of high blood pressure in the lungs.
- You started treatment with treprostinil (given under the skin or into a vein) on or after January 1, 2024.
- You are not participating in other clinical trials for PAH.
- Your pulmonary hypertension is not caused by other conditions like heart or lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called treprostinil to see if it is safe and effective for people with intermediate-risk pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. If you join, you may receive the study drug along with your usual PAH medications, which could help improve your symptoms and slow the disease.
This study tests whether switching from the oral medicine selexipag to an inhaled medicine called treprostinil can improve symptoms or side effects in people with pulmonary arterial hypertension (PAH). It may be an option if you are not getting enough benefit or are having trouble tolerating selexipag.
This program provides access to an inhaled medication called treprostinil for people who have pulmonary hypertension (high blood pressure in the lungs) related to interstitial lung disease (a type of lung scarring). The treatment aims to improve symptoms and quality of life.
This study tests whether taking injected treprostinil together with riociguat can improve how the heart and lung blood vessels work in people with advanced pulmonary artery hypertension (PAH). It may help improve blood-flow measurements and the structure of the heart.
This trial tests a medicine called treprostinil in children with severe pulmonary arterial hypertension (high blood pressure in the lungs). The study aims to see if it is safe and tolerable for kids who need this kind of therapy.
This trial tests whether an inhaled medication called treprostinil (which helps open blood vessels in the lungs) can improve exercise ability in people who get high blood pressure in the lungs only during exercise. Participation involves taking the medication and doing exercise tests to see how well you do.
Hear when a new Pulmonary Arterial Hypertension (PAH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.